Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response
Open Access
- 23 July 2024
- journal article
- research article
- Published by Wiley in Small Methods
- Vol. 9 (1) , e2400633
Abstract
Lipid nanoparticles encapsulating mRNA (LNP‐mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP‐mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP‐mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re‐administration of these cells. Here, it is shown that LNP‐mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti‐tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB inducing kinase (NIK) abrogated vaccination efficacy, demonstrating that adoptively transferred DCs can be functionally modified in addition to their antigen presentation capacity. Collectively, these studies show that ex vivo LNP‐mRNA engineering of DCs is a feasible and robust therapeutic strategy for cancer.Keywords
Funding Information
- National Cancer Institute (R33 CA277820, T32CA079443)
This publication has 48 references indexed in Scilit:
- Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory CapabilityAngewandte Chemie International Edition, 2024
- Hybrid LNP Prime Dendritic Cells for Nucleotide DeliveryAdvanced Science, 2023
- An old problem with new solutions: Strategies to improve vaccine efficacy in the elderlyAdvanced Drug Delivery Reviews, 2022
- Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticlesBioengineering & Translational Medicine, 2021
- Lipid nanoparticle technology for therapeutic gene regulation in the liverAdvanced Drug Delivery Reviews, 2020
- Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer ImmunotherapyCell Chemical Biology, 2020
- The Immune Revolution: A Case for Priming, Not CheckpointCancer Cell, 2018
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in CancerCell Reports, 2016
- Cyclooxygenase-Dependent Tumor Growth through Evasion of ImmunityCell, 2015
- Immunosuppressive Mechanisms of Regulatory Dendritic Cells in CancerCancer Microenvironment, 2013